Insciences organisation
Published on 25 February 2010, 03:39
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin increased the time women with advanced ovarian cancer lived without their disease worsening (progression-free survival or PFS) compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal...
The Sydney Morning Herald
DANNY ROSE
February 23, 2010
Source: AAP
Experts can report some "positive news" on ovarian cancer, as research shows a slight decrease in incidence of the often deadly and difficult to detect disease.
The Australian Institute of Health and Welfare and the National Breast and Ovarian Cancer Centre (NBOCC) have jointly released their latest data on the cancer.
It shows that in 2006 just over 1220 Australian...
Abbott's ARCHITECT human epididymis protein 4 (HE4) assay submitted for 510(k) clearance
ABBOTT PARK, Ill., Feb. 8 /PRNewswire-FirstCall/ -- A new diagnostic tool physicians can use to monitor patients for the most common form of ovarian cancer may soon be available in the United States. Abbott's ARCHITECT HE4 assay uses a simple blood test to help in monitoring for the recurrence or progression of epithelial ovarian cancer. If approved, this important immunoassay would be the first...
ScienceDaily (Feb. 8, 2010) — As cancer survivors live longer, questions arise about what kind of care long-term survivors require.
A recently published study from Case Western Reserve University's Mandel School of Applied Social Sciences found 245 older married women who survived cancer had more health problems as compared to a sample of 245 married women without cancer.
The article was published as part of a special supplement of the Journal of the American Geriatrics...
ScienceDaily (Feb. 4, 2010) — Scientists at Georgia Tech and the Ovarian Cancer Institute have further developed a potential new treatment against cancer that uses magnetic nanoparticles to attach to cancer cells, removing them from the body. The treatment, tested in mice in 2008, has now been tested using samples from human cancer patients. The results appear online in the journal Nanomedicine.
"We are primarily interested in developing an effective method to reduce the spread...
